Related Experiment Videos
Drugs Based on NMDAR Hypofunction Hypothesis in Schizophrenia.
Qiongqiong Wu1, Jing Huang1, Renrong Wu1
1Department of Psychiatry, National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, China.
Frontiers in Neuroscience
|April 29, 2021
Summary
Treatments targeting N-methyl-D-aspartate receptors (NMDARs) show promise for schizophrenia
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Schizophrenia treatments for negative symptoms and cognitive dysfunction are challenging.
- The N-methyl-D-aspartate receptor (NMDAR) hypofunction hypothesis is central to understanding schizophrenia.
- NMDAR antagonists and anti-NMDAR encephalitis inform this hypothesis.
Purpose of the Study:
- To review NMDAR-targeted drugs for schizophrenia.
- To analyze clinical study outcomes for negative symptoms and cognitive dysfunction.
- To offer perspectives on NMDAR-based therapeutic strategies.
Main Methods:
- Literature review of NMDAR-targeted drugs.
- Summarization of clinical studies on schizophrenia.
- Analysis of treatment outcomes based on the glutamate hypothesis.
Main Results:
- NMDAR-targeted drugs are being investigated for schizophrenia.
- Clinical studies show mixed results for negative symptoms and cognitive deficits.
- Analysis suggests reasons for unsatisfactory outcomes.
Conclusions:
- Augmenting NMDAR function is a potential therapeutic avenue.
- Further research is needed to optimize NMDAR-based treatments.
- Understanding the glutamate hypothesis is key for future strategies.